Qualigen Therapeutics Files 8-K: Material Definitive Agreement
Ticker: AIXC · Form: 8-K · Filed: Jul 18, 2024 · CIK: 1460702
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Qualigen Therapeutics signed a big deal on 7/12/24, details TBD.
AI Summary
On July 12, 2024, Qualigen Therapeutics, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, its terms, or any associated dollar amounts. It also lists financial statements and exhibits as part of the filing.
Why It Matters
This filing indicates a significant new agreement for Qualigen Therapeutics, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the 8-K filing regarding the material definitive agreement introduces uncertainty about its implications.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- July 12, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Qualigen Therapeutics?
The filing does not specify the nature of the Material Definitive Agreement.
When was the Material Definitive Agreement entered into?
The Material Definitive Agreement was entered into on July 12, 2024.
Are there any financial terms or dollar amounts associated with this agreement disclosed in the filing?
No, the filing does not disclose any specific financial terms or dollar amounts related to the agreement.
What other items are included in this 8-K filing besides the Material Definitive Agreement?
The filing also includes Financial Statements and Exhibits.
What is Qualigen Therapeutics, Inc.'s principal executive office address?
Qualigen Therapeutics, Inc.'s principal executive office is located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-07-18 17:00:41
Key Financial Figures
- $1,250,000 — Inc., a Nevada corporation ("Marizyme") $1,250,000 against which Marizyme had previously d
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex10-1.htm (EX-10.1) — 2KB
- ex10-1_001.jpg (GRAPHIC) — 434KB
- ex10-1_002.jpg (GRAPHIC) — 70KB
- 0001493152-24-028359.txt ( ) — 906KB
- qlgn-20240712.xsd (EX-101.SCH) — 3KB
- qlgn-20240712_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240712_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Promissory Note, dated July 12, 2024, issued by Qualigen Therapeutics, Inc. to Marizyme, Inc. 104 Cover Page Interactive Data File, formatting Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: July 18, 2024 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer